Citius Pharmaceuticals Inc (NASDAQ:CTXR) shares saw unusually-high trading volume on Thursday . Approximately 1,889,606 shares were traded during trading, an increase of 267% from the previous session’s volume of 514,682 shares.The stock last traded at $1.15 and had previously closed at $0.93.
CTXR has been the subject of several research analyst reports. ValuEngine upgraded shares of Citius Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, December 3rd. Zacks Investment Research upgraded Citius Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 22nd.
The firm has a market capitalization of $27.48 million, a price-to-earnings ratio of -0.98 and a beta of 1.05. The stock has a fifty day moving average of $0.74 and a two-hundred day moving average of $0.83.
About Citius Pharmaceuticals (NASDAQ:CTXR)
Citius Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok, which is in Phase III clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of hemorrhoids.
Recommended Story: Different Types of Derivatives
Receive News & Ratings for Citius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.